Shire in the hunt for promising new stem cell tech

The UK's Shire has been making a series of small-$3 million to $5 million-investments in stem cell developers as the CEO continues to hunt for viable new business opportunities. "The science is there," said Angus Russell, "the challenge is finding something you can turn into a business." Russell makes clear that he's taking a distinctly unsentimental approach to stem cell research, noting that he only wants to acquire technology that insurers will be willing to pay for. Report

Suggested Articles

NASH leaders weigh in on the need for a drug for the disease and the challenges in getting it to patients.

The $210 million fund began life by leading a $17 million series A round in Quellis Biosciences.

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.